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vs. 4.6 ± 8.9; P = 0.0029) and interventions (5.8 ± 11.1 vs. 0.7 ± 1.1; P = 0.0042). 
Only 11.6% of PD patients used an ambulance or transport organized by the dialysis 
center/sickness fund, compared with 67.8% for HD. The estimated annual cost for 
the public payer (PP) was c72,350 per HD and c55,343 per PD patient (i.e., 31% 
more). As in 2006 there were approximately 6400 patients on dialysis (90% on HD, 
10% on PD), the PP total cost is estimated to be around c452 million (2.45% of 2006 
health care budget). The dialysis procedure was the main cost driver (66% of costs) 
being 27% more expensive for HD. Hospital and ambulatory services were respec-
tively 28% and 45% more expensive for HD. CONCLUSIONS: The economic burden 
of dialysis is important in Belgium. Considering that survival of PD patients is at least 
as good as that of HD patients and that home-treatment reduces exposure to hospital 
pathogens, PD represents good value for money and should be considered in more 
patients.
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OBJECTIVES: A patient suffering from end stage renal disease (ESRD) has two treat-
ment options, lifelong dialysis or renal transplantation. The aim of this review is to 
determine economic cost of illness associated with renal transplantation and dialysis 
in ESRD in the United States (US). METHODS: The information was retrieved from 
databases including Medline, EMBASE, United States Renal Data System (USRDS), 
WHO and relevant grey literature. Studies reporting data for cost associated with 
transplantation and dialysis in ESRD in the US were included. RESULTS: In 2007, 
hemodialysis (HD) was initiated in 99,886 patients, peritoneal dialysis (PD) in 6376 
patients and transplantation in 2500 patients in the US. Total Medicare costs associ-
ated with these were $17.6 billion for HD, $949 million for PD and $1.9 billion for 
transplantation (USRDS 2009). Unadjusted average annual Medicare expenditure 
(2004 US$) for PD and HD as ﬁ rst modalities was $53,277 and $72,189 respectively 
(Shih 2005). Patients with HD were twice as likely to be hospitalised over a 12-month 
period compared to matched PD patients. The median health care costs associated 
with hospitalization were $173,507 for HD patients vs. $129,997 for PD patients 
(Berger 2009). The mean length of stay was signiﬁ cantly less for PD with 6.57 days 
(P < 0.0001) vs. 7.25 days for HD (Walker 2009). The mean cost of treating S. aureus 
bacteraemia in HD patients, including readmissions and outpatient costs, was $24,034 
per episode (Engemann 2005). Over a 25 year time horizon, renal transplantation 
resulted in signiﬁ cant cost savings with a cost of $376,577/patient and life expectancy 
of 7.4 years compared to $568,670/patient and life expectancy of 6.7 years with long 
term dialysis (Quinn 2007). CONCLUSIONS: Renal transplantation results in signiﬁ -
cant cost savings compared to long term dialysis. The total health care costs associated 
with hemodialysis are higher compared to peritoneal dialysis.
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OBJECTIVES: This analysis was done to assess if co-morbidities inﬂ uence the public 
payer (PP) cost of dialysis patients in Belgium. METHODS: The data from a cost 
study (retrospective chart review of 130 Belgian patients undergoing dialysis in 2006) 
was analyzed a posteriori. Baseline medical characteristics were used to compute the 
Charlson co-morbidity score (CCMS). Costs included: dialysis procedure and medical 
management (i.e., hospitalizations, outpatient visits and procedures, laboratory and 
imaging tests, and transport). Multivariate analyses were performed with the logarith-
mic transformation of costs as the dependent variable and CCMS, dialysis modality 
(hemodialysis: HD or peritoneal dialysis: PD) and gender as the independent variables. 
The regression model was weighted by number of patient months in the study. CCMS 
was categorized as low (<4), moderate (4–5), high (6–7) and very high (> = 8). 
RESULTS: All 3 variables had a signiﬁ cant impact on costs. Total costs to the PP were 
16% higher for HD than for PD patients (p = 0.0039) and were 13% higher in women 
than in men (p = 0.0207). The costs in patients with a very high CCMS were 21% 
higher than those with a low or moderate score (p = 0.0072 and p = 0.0094 respec-
tively) and 10.7% higher than those with a high score, but this latter difference did 
not reach statistical signiﬁ cance (p = 0.1160). The differences were larger when exclud-
ing the cost of dialysis procedure and considering medical management only, but only 
reached statistical signiﬁ cance or patients having a very high CCMS score vs. low or 
moderate CCMS (p = 0.0036 and 0.0056 respectively). CONCLUSIONS: This analy-
sis showed that patient co-morbidities have a signiﬁ cant impact on medical manage-
ment and total costs of dialysis patients. It is therefore important to take this into 
consideration when studying the costs of dialysis patients, especially if a total cost 
approach (i.e., procedure plus medical management) is taken.
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OBJECTIVES: Complications due to late dialysis referral after graft loss involve higher 
medical costs, together with a worsened health status and higher mortality rates. The 
efﬁ ciency of timely (TDR) versus late dialysis referral (LDR) after renal transplant failure 
is evaluated for the Spanish case. METHODS: A Markov model was developed and 6 
health states were deﬁ ned: hemodialysis (HD), peritoneal dialysis (PD), transplant (TX), 
late referral hemodialysis (LRHD), late referral peritoneal dialysis (LRPD) and death 
(D). a hypothetical cohort of patients aged 45 was observed during 40 years, considering 
age-dependent mortality rates. Transition probabilities were estimated using data from 
the Spanish Nephrology Society registry. Costs (in 2009 EUR) were obtained from a 
comprehensive literature review and included both direct (DC) (medical and non-
medical) and indirect costs (IC) (lost labor productivity due to mortality and morbidity). 
Effectiveness was measured in terms of Quality Adjusted Life-years (QALYs). Health 
utilities were estimated from a proprietary database. a discount rate of 3.5% was 
considered for both cost and effectiveness ﬁ gures. All the model parameters were sup-
ported by an expert panel. Incremental Cost-Effectiveness Ratios (ICERs) and Net 
Health Beneﬁ ts (NHBs) were computed. a willingness-to-pay threshold of c35,000/
QALY was taken into account. Both univariate and Monte Carlo multivariate sensitivity 
analyses were performed. RESULTS: The ICER was c27,385/QALY (IC not included) 
and c34,051/QALY [IC included], providing NHBs of (0.08) [0.01]. TDR yielded 0.37 
additional QALY/patient. The multivariate sensitivity analysis showed that TDR was 
efﬁ cient in (54%) [53%] and dominant in (28%) [27%] of the simulations. The prob-
ability of accepting TDR was (55%) [50%]. CONCLUSIONS: TDR is an efﬁ cient 
scenario when compared to LDR, providing a greater number of QALYs with yet an 
affordable increase in costs. Our results, however, raise the debate on the suitability of 
the willingness-to-pay threshold as a rigid decision tool.
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OBJECTIVES: To determine the most cost-effective alternative between a) Losartan, 
and b) Losartan + Aliskiren in type 2 diabetes and hypertension patients with micro-
albuminuria in the Mexican Institute of Social Security. METHODS: A complete 
economic evaluation was performed from institutional perspective, using a Markov 
model as analytical tool with semi-annual cycles and follow up until death, with 
transversal analyses at 10, 15 and 20 years. Simulating a cohort with a 53 years old 
patient with type 2 diabetes, hypertension, and microalbuminuria and using a dis-
counting rate of 5% in costs and effectiveness. One assumption is that all patients 
that require dialysis receive it. Proportion of patients who have not received dialysis, 
as well as survival and quality of life were considered as effectiveness end points. 
Transition probabilities were obtained from AVOID study and IMSS information. 
Resource use was obtained from IMSS data and costs are considered in 2009 USD. 
Probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: 
Keeping a patient in stages prior to dialysis at 20 years of follow-up requires an 
investment of $19,647 with Losartan and $18,774 with Losartan + Aliskiren. After 
14 years of follow up, Aliskiren + Losartan is dominant versus the use of Losartan. 
CONCLUSIONS: Aliskiren + Losartan is a cost-saving alternative if administered for 
prolonged periods, being the most effective regardless the period of monitoring and 
effectiveness measurement used.
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OBJECTIVES: To assess the cost-effectiveness between two non-calcium binders, 
lanthanum carbonate (LC) and sevelamer hydrochloride (SH), in end-stage renal 
disease (ESRD) patients previously treated with calcium-based binders. METHODS: 
A Markov model was developed to estimate incremental costs for three health out-
comes: 1) quality-adjusted life-years (QALYs), 2) Life-years saved (LYS) and 3) percent 
who successfully met serum phosphorus (SP) level goals (3.5–5.5 mg/dl) between the 
two non-Ca binders. The model incorporated patient-level data from a randomized 
head-to-head crossover study which compared the reduction of SP using ﬁ xed doses 
of LC for 4 weeks. For this analysis the model included patients previously treated 
with calcium-based binders. The ‘intent-to-treat’ (ITT) population and the ‘completer’ 
population were assessed. Baseline risks of cardiovascular disease (CVD), overall 
mortality, and CVD mortality were derived from a large US epidemiological study. 
Utilities, costs and relative risks of CVD were derived from published sources. Patient 
outcomes were modeled for 10 years, and incremental cost-effective ratios (ICERs) 
were calculated for LC relative to SH. Clinical and economic outcomes were dis-
